Key result
Various platelet inhibitors and anticoagulants play a role in the prevention of saphenous vein graft occlusion following coronary artery bypass grafting.
Why the study?
Do platelet inhibitors and anticoagulants prevent saphenous vein graft occlusion following coronary artery bypass grafting?
Do platelet inhibitors and anticoagulants prevent saphenous vein graft occlusion following coronary artery bypass grafting?
This review describes the role of antithrombotic therapies in preventing early and late saphenous vein graft occlusion after CABG.
Answers are grounded in this paper and cite their sources.
Supports antithrombotic strategies post-CABG; leaves open optimal regimens pending randomized data.
Coronary artery bypass grafting is an important therapeutic modality in the treatment of the patient with coronary artery disease; however, long-term results are limited by the development of saphenous vein graft disease early and late after operation. The pathogenesis of early vein graft occlusion is primarily thrombotic, while that occurring later frequently involves thrombosis superimposed on intimal hyperplasia or vein graft atherosclerosis. We describe the role of various platelet inhibitors and anticoagulants in the prevention of saphenous vein graft occlusion following coronary artery bypass grafting.
No takes yet. Share an insight, caveat, or question.
Israel et al. (1991) conducted a review in Coronary artery disease. Platelet inhibitors and anticoagulants was evaluated. Various platelet inhibitors and anticoagulants play a role in the prevention of saphenous vein graft occlusion following coronary artery bypass grafting.
Synapse has enriched 10 related papers. Consider them for comparative context: